Physician profile
Steven Schneiderman
NPI 1366415960
$5,958.83
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $837 · 2021: $1,371 · 2022: $1,327 · 2023: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $965.65 | 2019-2023 | Skyrizi, Linzess, Rinvoq |
| Janssen Biotech, INC. | $822.08 | 2019-2023 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $751.92 | 2019-2023 | Xifaxan, Plenvu, Trulance |
| Gilead Sciences, INC. | $511.18 | 2019-2022 | |
| Daiichi Sankyo INC. | $480.19 | 2019-2023 | Injectafer |
| Celgene Corporation | $407.62 | 2021-2023 | Zeposia |
| Pfizer INC. | $398.63 | 2019-2023 | |
| Genzyme Corporation | $329.21 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $204.71 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $177.92 | 2019-2023 | Dificid, Zinplava |
| Redhill Biopharma INC. | $151.52 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Janssen Scientific Affairs, LLC | $125.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $113.10 | 2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $105.55 | 2019-2023 | Linzess |
| Evoke Pharma, INC. | $81.75 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $44.59 | 2022-2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $42.78 | 2023 | Cimzia, Rebyota |
| Alfasigma USA, INC. | $42.04 | 2020 | |
| Qol Medical, LLC | $42.01 | 2019-2020 | |
| Braintree Laboratories, INC. | $39.21 | 2020-2022 | |
| Ucb, INC. | $26.89 | 2019 | |
| Nestle Healthcare Nutrition INC. | $25.42 | 2021-2022 | |
| Shire North American Group INC | $14.99 | 2019 | |
| Medtronic USA, INC. | $14.31 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.81 | 2020 | |
| Romark Laboratories, Lc | $13.80 | 2020 | |
| Ardelyx, INC. | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Schneiderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.